- Slice of Manufacturing
- Posts
- RevOpsis Therapeutics and Kemwell Biopharma Form Strategic Manufacturing Partnership
RevOpsis Therapeutics and Kemwell Biopharma Form Strategic Manufacturing Partnership
Slice of Manufacturing Team
June 30, 2024
Key Highlights:
RevOpsis and Kemwell Biopharma announce strategic manufacturing partnership.
Collaboration focuses on developing RO-104, a tri-specific biologic for nAMD.
Kemwell to leverage its cGMP manufacturing expertise for RO-104 production.
RO-104 targets VEGF-A, VEGF-C, and Ang-2 pathways, aiming to redefine nAMD treatment.
Partnership accelerates transition from pre-clinical to clinical trials.
Source (PR Newswire)
Notable Quotes
"Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics."
"Our expertise in complex protein manufacturing, coupled with RevOpsis' innovative therapeutic approaches, holds great promise for advancing the treatment of retinal vascular diseases."
Our Take:
This strategic partnership between RevOpsis Therapeutics and Kemwell Biopharma marks a significant milestone in the biopharmaceutical landscape, particularly in the field of ophthalmic therapies. By combining RevOpsis' innovative Rev-Mod platform with Kemwell's established manufacturing capabilities, the collaboration is set to accelerate the development of RO-104, a groundbreaking tri-specific biologic targeting critical angiogenic pathways in nAMD. This alliance not only aims to expedite the transition from pre-clinical to clinical phases but also has the potential to significantly improve treatment outcomes for patients suffering from retinal vascular diseases. The partnership is a testament to the growing trend of leveraging strategic collaborations to advance medical innovations and bring transformative therapies to market more efficiently.